Merck & Company Inc (MRK)vsRadNet Inc (RDNT)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
RDNT
RadNet Inc
$75.49
+1.63%
HEALTHCARE · Cap: $5.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2834% more annual revenue ($66.57B vs $2.27B). MRK leads profitability with a 4.8% profit margin vs -0.9%. RDNT appears more attractively valued with a PEG of 0.96. RDNT earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold36
out of 100
Grade: F
RDNT
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for RDNT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Growing faster than its price suggests
Revenue surging 25.0% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Elevated debt levels
Weak financial health signals
ROE of -1.3% — below average capital efficiency
Earnings declined 49.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RDNT
The strongest argument for RDNT centers on PEG Ratio, Revenue Growth. Revenue growth of 25.0% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RDNT
The primary concerns for RDNT are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.99 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while RDNT is a growth play — different risk/reward profiles.
RDNT carries more volatility with a beta of 1.40 — expect wider price swings.
RDNT is growing revenue faster at 25.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
RDNT scores higher overall (44/100 vs 36/100) and 25.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →RadNet Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
RadNet, Inc., provides outpatient imaging services in the United States. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?